Your new post is loading...
The European Biotech News Website
Research and publish the best content.
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Already have an account: Login
Genetic Engineering in the Press by GEG
36.1K views |
+2 today
In a blow to the field of mRNA, the German billion-euro biotech CureVac has reported the Phase II failure of its lead candidate at JP Morgan. Aimed at prostate cancer, CV9104 did not meet its primary endpoint of improving overall survival, though it achieved a secondary safety endpoint.